Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development

Key Takeaways

• Dr. Michael Panzara joins Immunic as Chief Medical Officer with proven expertise in multiple sclerosis drug development and regulatory approvals
• Appointment strengthens Immunic’s leadership team as Vidofludimus Calcium advances through pivotal clinical development for neurologic diseases
• Panzara’s experience with late-stage clinical programs positions Immunic for potential global regulatory submissions and approvals

---

NEW YORK - Immunic, Inc. (Nasdaq: IMUX) announced the appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, bringing decades of neurology drug development expertise to the late-stage biotechnology company as it advances its lead candidate Vidofludimus Calcium through pivotal trials.

Dr. Panzara joins Immunic with an established track record in developing approved multiple sclerosis therapies and advancing late-stage clinical programs through global regulatory approvals. His appointment comes at a critical juncture as Immunic prepares to advance Vidofludimus Calcium, an oral therapy targeting neurologic diseases, through pivotal development phases.

Strategic Leadership Addition

The appointment reinforces Immunic’s commitment to building a world-class leadership team capable of navigating complex regulatory pathways. Dr. Panzara’s experience spans multiple successful drug launches in the competitive neurology market, where regulatory expertise and clinical trial design prove crucial for approval success.

Immonic’s focus on oral therapies for neurologic diseases addresses a significant market need, with multiple sclerosis affecting over 2.8 million people worldwide. The company’s approach with Vidofludimus Calcium represents a potential advancement in treatment options for patients seeking effective oral alternatives.

Market Implications

The pharmaceutical industry increasingly values experienced leadership in neurology drug development, particularly given the complex regulatory requirements and competitive landscape. Dr. Panzara’s appointment signals Immunic’s readiness to execute on late-stage development milestones and potential commercialization strategies.

With Vidofludimus Calcium progressing through clinical development, the addition of proven regulatory and clinical expertise positions Immunic to potentially accelerate timelines and improve approval probability. The appointment reflects broader industry trends toward recruiting executives with specific therapeutic area expertise and regulatory success records.

Investors and stakeholders will likely monitor upcoming clinical milestones and regulatory interactions as Immunic advances its pipeline under new medical leadership.

---

Frequently Asked Questions

What does this appointment mean for Vidofludimus Calcium development?

Dr. Panzara’s expertise in multiple sclerosis drug development and regulatory approvals should help accelerate Vidofludimus Calcium through pivotal trials and potential regulatory submissions.

When will Vidofludimus Calcium be available to patients?

The drug is currently in pivotal development phases. Timeline for potential approval depends on clinical trial results and regulatory review processes, typically taking several years.

How does Vidofludimus Calcium compare to existing neurologic treatments?

As an oral therapy for neurologic diseases, Vidofludimus Calcium aims to provide patients with a convenient alternative to injectable treatments, though efficacy and safety data from ongoing trials will determine its competitive position.